Bharat Biotech seeks nod for Covaxin in 60+ countries

Vaccine innovator Bharat Biotech International has sought approval for its indigenously developed Covid-19 vaccine Covaxin in more than 60 countries including the United States, Brazil and Hungary, among others.

In a statement on Tuesday evening, the vaccine maker said it has obtained emergency use authorisations from 13 countries so far and more were in the process.

The countries that granted emergency use licences (EUL) include Mexico, Philippines, Iran, Paraguay, Guatemala, Nicaragua, Guyana, Venezuela, Botswana, Zimbabwe, among others.


Bharat Biotech said it has also submitted an EUL application with the World Health Organisation (WHO) and expects the regulatory approvals by the July-September quarter.

Raches Ella, head of business development and international advocacy at Bharat Biotech, told a conference of women entrepreneurs in Hyderabad on Saturday that the vaccine maker was in the process of obtaining pre-qualification approvals for Covaxin from the WHO. “A few of our products in the past got their (WHO’s) approval. We expect approval for Covaxin by the end of Q3 or Q4.”